Cefiderocol-Based Combination Therapy for "Difficult-to-Treat" Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives

• Main Authors: Davide Fiore Bavaro (Author), Alessandra Belati (Author), Lucia Diella (Author), Monica Stufano (Author), Federica Romanelli (Author), Luca Scalone (Author), Stefania Stolfa (Author), Luigi Ronga (Author), Leonarda Maurmo (Author), Maria Dell'Aera (Author), Adriana Mosca (Author), Lidia Dalfino (Author), Salvatore Grasso (Author), Annalisa Saracino (Author)
• Formato: Libro
• Publicado: MDPI AG, 2021-05-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Cefiderocol is a new cephalosporin displaying against extensively resistant (XDR) Gram-negative bacteria. We report our experience with cefiderocol-based combination therapies as "rescue" treatments in immunocompromised or critically ill patients or in patients with post-surgical infection...